This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...
This news release constitutes a“designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021 ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する